focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Might just get away with it
BAE are up for buying just about anything at the moment, swimming in cash and orders and determined to double in size
Great win here, more in the pipeline coming
The approval was based on phase 2 study results in 90 patients who received 200 mg of Keytruda intravenously every three weeks. Out of 41 patients who responded to the treatment, 68 percent had responses lasting 12 months or longer and 44 percent had responses lasting 24 months or longer.
Impressive GLA
To the moon Porky, good luck